Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024.
IF 25.4 1区 医学Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Erica E Zeno, Francisco Nogareda, Annette Regan, Paula Couto, Marc Rondy, Jorge Jara, Carla Voto, Maria Paz Rojas Mena, Nathalia Katz, Maria Del Valle Juarez, Estefanía Benedetti, Francisco José de Paula Júnior, Walquiria Aparecida Ferreira da Almeida, Carlos Edson Hott, Paula Rodríguez Ferrari, Natalia Vergara Mallegas, Marcela Avendaño Vigueras, Chavely Domínguez, Marta von Horoch, Cynthia Vazquez, Eduardo Silvera, Hector Chiparelli, Natalia Goni, Laura Castro, Perrine Marcenac, Rebecca J Kondor, Juliana Leite, Martha Velandia, Eduardo Azziz-Baumgartner, Ashley L Fowlkes, Daniel Salas
{"title":"Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024.","authors":"Erica E Zeno, Francisco Nogareda, Annette Regan, Paula Couto, Marc Rondy, Jorge Jara, Carla Voto, Maria Paz Rojas Mena, Nathalia Katz, Maria Del Valle Juarez, Estefanía Benedetti, Francisco José de Paula Júnior, Walquiria Aparecida Ferreira da Almeida, Carlos Edson Hott, Paula Rodríguez Ferrari, Natalia Vergara Mallegas, Marcela Avendaño Vigueras, Chavely Domínguez, Marta von Horoch, Cynthia Vazquez, Eduardo Silvera, Hector Chiparelli, Natalia Goni, Laura Castro, Perrine Marcenac, Rebecca J Kondor, Juliana Leite, Martha Velandia, Eduardo Azziz-Baumgartner, Ashley L Fowlkes, Daniel Salas","doi":"10.15585/mmwr.mm7339a1","DOIUrl":null,"url":null,"abstract":"<p><p>To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 39","pages":"861-868"},"PeriodicalIF":25.4000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449270/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7339a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.
为了降低与流感相关的发病率和死亡率,南美国家建议每年为重症流感高危人群接种流感疫苗,包括幼儿、原有健康状况者和老年人。南半球国家对流感疫苗有效性(VE)的临时估计可以提供有关疫苗接种保护效果的早期信息,并帮助北半球国家在流感季节到来之前提供指导。研究人员利用来自一个多国网络的数据,采用试验阴性病例对照设计估算了流感相关严重急性呼吸道疾病(SARI)住院治疗的临时有效率。在2024年3月13日至7月19日期间,阿根廷、巴西、智利、巴拉圭和乌拉圭共发现了11751例流感相关SARI病例;平均21.3%的患者接种了流感疫苗,调整后的住院风险系数为34.5%。针对主要亚型甲型 H3N2 的调整 VE 为 36.5%,针对甲型 H1N1 pdm09 的调整 VE 为 37.1%。这些临时 VE 估计值表明,虽然接种疫苗的住院病人比例不大,但接种南半球流感疫苗可显著降低住院风险。因此,北半球国家应预计到有必要大力开展流感疫苗接种活动和早期抗病毒治疗,以达到预防流感相关并发症的最佳效果。
期刊介绍:
The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC).
Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.
MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.